Patent Application
20110088613
The present invention relates to a process for controlling the growth of a raloxifene hydrochloride crystal.
State of the Art
Raloxifene and in particular the relative hydrochloride salt, characterized by the following formula (I):
is an active principle used in the treatment of osteoporosis and was described for the first time in European patent application EP62503. According to said patent, the active principle is obtained in the form of a hydrochloride at low yields by a process that comprises a purification step by column chromatography to remove certain by-products.
With the aim of improving the yield and purity of the product, in the international patent application WO2005/003116 a multi-step process for obtaining raloxifene hydrochloride is described, which is characterized by a step of hydrolyzing 6-acetoxy-2-(4-acetoxyphenyl)3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene with alkaline hydroxide in an alcoholic solvent and subsequent acidification of the obtained product with concentrated hydrochloric acid. According to that described in the international patent application, crude raloxifene hydrochloride is obtained with a purity equal to about 98% and a yield of about 65-70%.
Specifically, example 3 of the international application describes the obtaining of crystallized raloxifene hydrochloride with a purity of 99%, which can then be further purified, as described in example 4, in methanol and water in the presence of 37% hydrochloric acid to increase its purity. The product obtained in this manner has an HPLC purity higher than 99.8% with particle size characteristics such that D(0.9) is ≦100 μm and D(0.5) is ≧40 μm. Following a further sieving step, the product presented the following particle size characteristics: D(0.9) comprised between 50 and 65 μm and D[4.3]≧20 μm.
For the purpose of marketing the raloxifene hydrochloride product, it is felt the need that the product can have different product particle size distributions, and not necessarily with particle size characteristics of D(0.9)≦100 μm and D(0.5)≧40 μm.
The object of the present invention is therefore to provide control of granule growth, i.e. the size of single raloxifene hydrochloride crystals, during implementation of the process itself, so as to obtain a precise and desired final raloxifene hydrochloride crystal size.
The aforementioned object was achieved by means of a process for controlling the growth of a raloxifene hydrochloride crystal which comprises the steps of:
a) heating under reflux a mass comprising crystalline raloxifene hydrochloride, methanol and water for a time of about 10 minutes,
b) cooling the mass to 30-35° C.,
c) checking the crystal size,
wherein steps a), b) and c) are repeated for a number of cycles n, until the desired crystal size is obtained.
In a preferred embodiment, the number of cycles n is in the range from 2 to 5 in order to obtain a final raloxifene hydrochloride granule size which is in the particle size characteristics of D(0.9)≦100 μm and D(0.5)≧35 μm.
The invention therefore relates to a process for controlling raloxifene hydrochloride crystal growth, i.e. for controlling the size of the raloxifene hydrochloride crystal, which comprises the steps of: a) heating under reflux a mass comprising crystalline raloxifene hydrochloride, methanol and water for a time of about 10 minutes, b) cooling the mass to 30-35° C., and c) checking the crystal size, wherein the steps a), b) and c) are repeated for a number of cycles n until the desired crystal size is obtained.
The crystalline raloxifene hydrochloride compound of step a) is preferably obtained as described in the international patent application WO2005/003116, i.e. by crystallization of crude raloxifene hydrochloride in alcoholic solvent, preferably from a mass comprising methanol-water in the presence of HCl. More preferably, according to the invention, the weight ratio of water to methanol in the mass for obtaining the crystallized raloxifene of step a) from crude raloxifene hydrochloride is about 1:12.
The crude raloxifene hydrochloride from which the crystalline raloxifene hydrochloride of step a) is obtained, is preferably obtained by the process described in international patent application WO2005/003116, which is included herein for reference, in particular for examples 1 and 2 which lead to the obtainment of crude raloxifene hydrochloride.
The weight ratio of water to methanol in step a) is preferably about 1:90 and the reflux temperature is in the range from 65 to 67° C.
Without wishing to be bound to any theory, the inventors have found that the maintenance time at reflux of 10 minutes is a sufficient time and necessary for the purpose of achieving an effective control of raloxifene hydrochloride crystal size during implementation of the process for preparing crystalline raloxifene hydrochloride.
In step b) of cooling to 30-35° C., crystal growth is interrupted.
The cooling step b) is followed by the crystal size checking step c). Said step preferably comprises sampling of the reaction mass, filtering and drying the sample followed by checking the particle size distribution by a laser technique on the sample. Following to step c), the size of the sample will be representative of the crystal sizes present in the reactor.
According to the process of the invention, therefore, the mass of step a) is heated under reflux for about 10 minutes, then cooled to 30-35° C. in step b), after which the size achieved by the crystal is checked. The number of cycles n, will therefore vary according to the desired crystal size. The number of cycles will be greater the greater the required crystal size.
Once the desired crystal size has been achieved through sampling of the crystal and a suitable number of cycles, the cooled mass is distilled under vacuum to remove a part of the solvent without further increasing particle size of the crystalline product.
In a preferred embodiment the final crystal has a particle size distribution of D(0.9)≦100 μm and D(0.5)≧35 μm.
In this case the number of repeating cycles n of steps a)-c) is in the range 2-5.
The invention will now be described by referring to some examples of the process of the invention for obtaining the desired particle size distribution of the raloxifene hydrochloride crystal by way of non-limiting illustration.
228 kg of water, crude raloxifene hydrochloride corresponding to 152 kg of dry product (prepared as described in example 2 of international patent application WO2005/003116) and 2711 kg of methanol were loaded into a reactor.
The mass was heated to 62-68° C. until completely dissolved, then treated with a suspension of 6.4 kg of decolorizing carbon in 25.3 kg of methanol.
After having removed the carbon by filtration, 1693 kg of methanol were distilled off.
The residue was cooled to 30°-35° C. and 2.54 kg of 37% hydrochloric acid were added until pH 2.0 was reached.
The mass was stirred at 30-35° C. for at least 2 hours then centrifuged, washing with 152 kg of cold methanol.
The wet product was then used (after determining loss on drying) in the next step for obtaining raloxifene hydrochloride of the desired particle size.
Based on the loss on drying, the quantity of obtained crude product was 109 kg.
22 kg of water, crystallized raloxifene hydrochloride obtained from example 1 with D(0.5)=15.7 μm and D(0.9)=45.3 μm corresponding to 109 kg of dry product, and 1962 kg of methanol were loaded into a reactor.
The mass was heated under reflux for about 10 minutes, then cooled to 25-35° C. and the particle size distribution was checked on a small sample withdrawn from the reactor.
The cycle which comprised heating under reflux for about 10 minutes, cooling to 25-35° C. and checking particle size by withdrawing a sample, was repeated four times to obtain the particle size distribution values shown in the following Table 1:
When growth was complete, 982 kg of methanol were distilled off under vacuum. The residue was cooled to 30-35° C. and 2.18 kg of 37% hydrochloric acid were added until pH≦2.0 was reached.
The mass was stirred at 30-35° C. for at least 2 hours, then the suspension was centrifuged, washing with 109 kg of cold methanol.
The wet product was dried at 70-80° C.
The dry product was passed through a granulator (moderate grinding conducted with the aim of homogenising the product).
97 kg of dry product with D(0.1)=10.3 μm D(0.5)=41.2 μm and D(0.9)=93.0 μm were obtained.
By using the same ingredients and amounts and following the procedure of example 2, but starting from the crystallized raloxifene of example 1 with D(0.5)=18.4 μm and D(0.9)=53.2 μm, the steps of heating under reflux, cooling and checking were carried out three times to obtain the particle sizes indicated in the following Table 2.
The product leaving the third treatment cycle was then dried and granulated as in example 2 to obtain raloxifene hydrochloride with D(0.1)=10.0 μm D(0.5)=36.6 μm and D(0.9)=86.7 μm.
By using the same ingredients and amounts and following the procedure of example 2, but starting from the crystallized raloxifene of example 1 with D(0.5)=14.7 μm and D(0.9)=39.5 μm the steps of heating under reflux, cooling and checking were carried out five times to obtain the particle sizes indicated in the following Table 3.
The product leaving the fifth treatment cycle was then dried and granulated as in example 2 to obtain raloxifene hydrochloride with D(0.1)=8.5 μm D(0.5)=38.4 μm and D(0.9)=87.7 μm.
By using the same ingredients and amounts and following the procedure of example 2, but starting from the crystallized raloxifene of example 1 with D(0.5)=14.7 μm and D(0.9)=39.5 μm the steps of heating under reflux, cooling and checking were carried out twice to obtain the particle sizes indicated in the following Table 4.
The product leaving the second treatment cycle was then dried and granulated as in example 2 to obtain raloxifene hydrochloride with D(0.1)=5.7 μm D(0.5)=37.4 μm and D(0.9)=94.1 μm.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IT08/00380 | 6/9/2008 | WO | 00 | 12/8/2010 |
